Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$223.48 USD

223.48
389,964

+0.13 (0.06%)

Updated May 25, 2022 04:00 PM ET

After-Market: $223.35 -0.13 (-0.06%) 7:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.08%
2Buy18.56%
3Hold10.15%
4Sell5.79%
5Strong Sell2.83%
S&P50011.24%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 24% (192 out of 253)

Industry: Medical Services

Trades from $1

Zacks News

Here's Why You Should Retain Charles River (CRL) Stock for Now

Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.

    Charles River (CRL) DSA Arm Prospers, Currency Headwind Stays

    Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.

      Charles River (CRL) Q1 Earnings Top, Gross Margin Falls

      Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.

      Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates

      Charles River (CRL) delivered earnings and revenue surprises of 1.48% and 0.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

      Urmimala Biswas headshot

      MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA

      MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.

      Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?

      Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Charles River (CRL) to Report Q1 Earnings: What's in Store?

      Robust global demand for the research model and multiple initiatives to expedite the discovery process are likely to have contributed to Charles River's (CRL) first-quarter results.

      Charles River (CRL) Buys Explora BioLabs to Expand in CRO Space

      Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.

      Here's Why You Should Retain Charles River (CRL) Stock For Now

      Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.

      Charles River Laboratories (CRL) is a Top-Ranked Value Stock: Should You Buy?

      Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

      Why Is Charles River (CRL) Down 3.4% Since Last Earnings Report?

      Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      CoDiagnostics, Inc. (CODX) Surges 13.1%: Is This an Indication of Further Gains?

      CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

      Neena Mishra headshot

      Inflation Beneficiary ETFs in Focus as Prices Soar

      These ETFs invests in assets that benefit from inflation

      Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

      Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

      Here's Why You Should Retain Charles River (CRL) Stock For Now

      Investors are optimistic about Charles River (CRL) on robust demand in Biologics Testing Solutions and Microbial Solutions businesses.

      Charles River (CRL) DSA Arm Sees Growth, Cell Supply Sluggish

      The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.

      Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now

      Robust domestic and international performances by the CAG arm are driving IDEXX's (IDXX) fourth-quarter top line.

      Tandem Diabetes (TNDM) to Offer Insulin Delivery With Smartphone

      Tandem Diabetes' (TNDM) t:connect is the first-ever app on both iOS and Android operating systems to receive FDA clearance for insulin delivery from a personal smartphone.

      Charles River (CRL) Q4 Earnings Beat Estimates, Margins Up

      Robust demand for research models, particularly in China, as well as higher revenues from research model services aid Charles River (CRL) in Q4.

      Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates

      Charles River (CRL) delivered earnings and revenue surprises of 2.89% and 1.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

      Sanghamitra Saha headshot

      Land on 5 Winning Stocks With the Overlooked Rising P/E Trick

      Stocks with rising P/E often proves to be an intriguing investing idea.

      Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now

      Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.

      Charles River (CRL) to Report Q4 Earnings: What's in Store?

      The acquisitions of Vigene Biosciences and Cognate are likely to have a full-quarter favorable impact on Charles River's (CRL) Q4 Manufacturing Support revenues.

      Charles River Laboratories (CRL) Reports Next Week: Wall Street Expects Earnings Growth

      Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

      Investors are optimistic about Bio-Rad's (BIO) strong growth within Life Science and Clinical Diagnostics segments across all regions.